Oncology Collaboration and Licensing Deals 2021-2026

$4,995.00

Select license type

Single user (one user/device)

Multi-user (up to five users/devices) + $2,000.00

Corporate PDF + $4,000.00

Qty

2,955 oncology partnering deals | Financial benchmarks | Leading dealmakers and prospective partners | Therapeutic indication and target analysis | Contract intelligence

Publication date

October 2026

Number of pages

1400+

Product type

Research report

Report edition

SKU

CP2201

Details

Oncology Collaboration and Licensing Deals 2021–2026

Understand the oncology partnering landscape using intelligence from real-world collaboration and licensing deals.

Oncology Collaboration and Licensing Deals 2021–2026 provides comprehensive intelligence on 2,955 partnering dealsinvolving oncology assets, technologies and development programs.

Oncology remains one of the most active areas of pharmaceutical and biotechnology partnering, with companies using collaboration and licensing to access novel targets, therapeutic modalities, development programs and commercial opportunities across a rapidly evolving treatment landscape.

The report brings this extensive deal activity together in one resource, enabling users to understand who is partnering, which oncology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Free report sample

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in oncology partnering.

Understand the oncology partnering landscape

The report analyzes oncology dealmaking from 2021 to 2026, including:

Trends in oncology partnering by year
Deal activity by deal type
Industry sector
Stage of development at the time of partnering
Technology type
Therapeutic indication
Most active oncology dealmakers
Leading deals by disclosed value
How oncology partnering activity is evolving

This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.

Benchmark oncology deal financials

Financial terms in oncology can vary significantly according to the asset, development stage, technology, competitive landscape, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

Headline deal values
Upfront payments
Milestone payments
Royalty rates

Users can investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.

This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.

Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.

Identify leading oncology dealmakers and prospective partners

The report identifies the most active companies in oncology partnering and provides extensive transaction histories that enable users to investigate their previous activity.

This can help users identify:

Companies actively seeking oncology opportunities
Prospective licensing and collaboration partners
Organizations repeatedly partnering in relevant cancer indications
Companies active at relevant stages of development
Dealmakers demonstrating interest in particular targets, technologies or therapeutic modalities
Competitors pursuing related external innovation strategies

For companies seeking to partner an oncology asset or technology, previous transaction activity can provide valuable evidence of which organizations have demonstrated an appetite for comparable opportunities.

Compare partnering activity across oncology indications and targets

Oncology encompasses a very broad range of cancer indications, biological targets and therapeutic approaches, each with different scientific, clinical and commercial dynamics.

The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad oncology benchmarks and focus on transactions most relevant to a particular program or strategic interest.

Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.

Understand how oncology agreements are structured

The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

Rights granted and retained
Research and development responsibilities
Licensing rights
Exclusivity
Geographic rights
Intellectual property
Development and regulatory obligations
Manufacturing and supply responsibilities
Commercialization rights
Financial consideration
Milestones and royalties
Governance
Term and termination provisions

These real-world examples provide useful reference points when considering the appropriate structure for an oncology partnership.

Learn from real-world contract documents

Where publicly available, the report provides access to underlying contract documents for selected oncology transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

Scope of rights
Development obligations
Intellectual property
Exclusivity
Financial terms
Milestone triggers
Royalty provisions
Commercialization rights
Termination and other negotiated provisions

For teams preparing or negotiating an oncology collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.

Comprehensive oncology deal directory

The report includes a comprehensive directory of 2,955 oncology collaboration and licensing deals, providing an extensive resource for identifying relevant precedent transactions.

Deals can be reviewed by:

Company
Technology type
Therapeutic indication or target
Contract availability

Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.

Who should use this report?

Business Development and Licensing teams
Identify comparable oncology transactions, prospective partners and relevant deal structures.

Search and Evaluation teams
Understand which companies are actively seeking oncology opportunities across relevant indications, technologies, targets and development stages.

Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable oncology assets and technologies.

Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building oncology portfolios through external innovation.

Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.

Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.

Senior Management and Portfolio Strategy teams
Understand where capital, partnering attention and external innovation activity are being concentrated across the oncology landscape.

Turn market-wide oncology intelligence into company-specific insight

For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.

The briefing applies the underlying oncology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.

Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.

Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Benefits

Key Benefits

✔ Benchmark against 2,955 oncology partnering deals – Access one of Current Partnering’s largest therapy-area datasets to identify relevant precedents and comparable transactions.

✔ Benchmark oncology deal financials – Analyze disclosed headline values, upfront payments, milestones and royalty rates and investigate the individual transactions behind the benchmarks.

✔ Identify prospective partners and leading dealmakers – Discover companies with demonstrated interest in oncology assets, technologies, therapeutic indications, targets and relevant stages of development.

✔ Compare activity across the oncology landscape – Analyze dealmaking by therapeutic indication and target, development stage, technology type, deal type, industry sector and company.

✔ Find the most relevant comparable transactions – Move beyond broad averages to identify deals involving similar indications, targets, modalities, technologies, development stages and partnering structures.

✔ Understand how oncology deals are structured – Examine licensing rights, development responsibilities, exclusivity, IP, commercialization rights, milestones, royalties and other important transaction provisions.

✔ Learn from real contract documents – Where publicly available, review underlying agreements to understand how rights, obligations, financial terms and other negotiated provisions have been documented.

✔ Apply the intelligence to your own oncology opportunity – Qualifying customers may also be eligible for a Customized Executive Partnering Briefing focused on their own asset, indication, target, technology, prospective partners or transaction objectives.

Table of contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in oncology dealmaking

2.1. Introduction

2.2. Oncology partnering over the years

2.3. Oncology partnering by deal type

2.4. Oncology partnering by industry sector

2.5. Oncology partnering by stage of development

2.6. Oncology partnering by technology type

2.7. Oncology partnering by therapeutic indication

Chapter 3 – Financial deal terms for oncology partnering

3.1. Introduction

3.2. Disclosed financials terms for oncology partnering

3.3. Oncology partnering headline values

3.4. Oncology deal upfront payments

3.5. Oncology deal milestone payments

3.6. Oncology royalty rates

Chapter 4 – Leading oncology deals and dealmakers

4.1. Introduction

4.2. Most active in oncology partnering

4.3. List of most active dealmakers in oncology

4.4. Top oncology deals by value

Chapter 5 – Oncology contract document directory

5.1. Introduction

5.2. Oncology partnering deals where contract document available

Chapter 6 – Oncology dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by oncology therapeutic target

Deal directory

Deal directory – Oncology deals by company A-Z

Deal directory – Oncology deals by technology type

Deal type definitions

About Biopharma Research Ltd

Current Partnering

Current Agreements

Recent report titles from Current Partnering

Table of figures

Figure 1: Oncology partnering since 2021

Figure 2: Oncology partnering by deal type since 2021

Figure 3: Oncology partnering by industry sector since 2021

Figure 4: Oncology partnering by stage of development since 2021

Figure 5: Oncology partnering by technology type since 2021

Figure 6: Oncology partnering by indication since 2021

Figure 7: Oncology deals with a headline value

Figure 8: Oncology deals with upfront payment values

Figure 9: Oncology deals with milestone payment

Figure 10: Oncology deals with royalty rates

Figure 11: Active oncology dealmaking activity since 2021

Figure 12: Top oncology deals by value since 2021

Pricing

Pricing options

$4,995: single-user (encrypted file - one user/device)
$6,995: multi-user (encrypted file - up to 5 users/devices)
$8,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

Our guarantee

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

Companies mentioned

1ST Biotherapeutics, 2seventy bio, 3B Pharmaceuticals, 3D Medicines, 3SBio, 3T Biosciences, 4baseCare, 4C Biomed, 4D Pharma, 9 Meters Biopharma, 10X Genomics, 20n Bio, 48Hour Discovery, 111, A*STAR Agency for Science, Technology and Research, A*STAR Bioprocessing Technology Institute, A*STAR’ Institute of Molecular and Cell Biology, Aadi Bioscience, Aarvik Therapeutics, Abbisko Therapeutics, Abbott Laboratories, Abbvie, Abcam, AbCellera Biologics, Abdul Latif Jameel Health, AbelZeta Pharma, Abera Bioscience, Abilita Bio, Abilita Therapeutics, Abintus Bio, Ablaze Pharmaceuticals, ABL Bio, Ab Magnitude Ventures, Abound Bio, Abpro, Abramson Cancer Center, AbSci, AbTherx, AbTis, ABVC BioPharma, Abveris, ABX, Abzena, Accelerated Biosciences, Accent Therapeutics, Access to Comprehensive Genomic Profiling Coalition, Acclinate, AccuStem Sciences, Acepodia, Acerand Therapeutics, Achilles Therapeutics, Acibadem University, Acrivon Therapeutics, Acrotech Biopharma, Actimed Therapeutics, Actinium Pharmaceuticals, ACT Therapeutics, Actuate Therapeutics, Acuitas Therapeutics, Adagene, AdAlta, Adaptimmune, Adaptive Biotechnologies, Adcendo, ADC Therapeutics, Adicet Bio, Adimab, Adlai Nortye, Advancell, Aerogen, Aethon Therapeutics, Affimed Therapeutics, Affini-T Therapeutics, Affinia Therapeutics, AFT Pharmaceuticals, AGC Biologics, Agena Bioscience, Agencja Badan Medycznych, Agendia, Agenus Bio, AgeX Therapeutics, Agilent Technologies, AgonOx, Aignostics, AIkido Pharma, AimedBio, AIM ImmunoTech, Ainos, Aion Therapeutic, AI Proteins, Aitia, AiVita Biomedical, Ajax Therapeutics, Ajinomoto, Akamis Bio, Akeso Biopharma, Akoya Biosciences, AKSO Biopharmaceutical, Akston Biosciences, Aktis Oncology, Alamar Biosciences, Alaya.bio, Alcedis, Alchemab, Alessa Therapeutics, Aleta Biotherapeutics, Alex’s Lemonade Stand Foundation, Alida Biosciences, Alkyon Therapeutics, Allarity Therapeutics, Allelica, Alligator Bioscience, Allist Pharma, Allogene Therapeutics, Alloplex Biotherapeutics, Allorion Therapeutics, Alloy Therapeutics, Almac Discovery, Almirall, Alpha Biopharma, Alphamab Biopharmaceuticals, Alphamab Oncology, Alpha Tau Medical, Alpine Immune Sciences, Altamira Therapeutics, Alteogen, Alvotech, ALX Oncology, Amasa Therapeutics, Ambry Genetics, Amgen, AmMax Bio, Amneal Pharmaceuticals, Amoy Diagnostics, Amphista Therapeutics, AnchorDx, Angiogenesis Foundation, Angle, AnHeart Therapeutics, Anima Biotech, Anivive Lifesciences, Anixa Biosciences, Anji Pharma, Ankyra Therapeutics, Anocca AB, Anova Enterprises, Anpac Bio-Medical Science, Antengene, Anthony Nolan, Anthropic, Antiverse, Apeiron Biologics, Apexigen, Apmonia Therapeutics, Apollomics, Apollon Formularies, Apollo Therapeutics, Appia Bio, Applied BioMath, Applied Biomedical Science Institute, Applied Cells, Aprea Therapeutics, Aptorum Group, Aptose Biosciences, Aqemia, Araris Biotech, ARase Therapeutics, Arbor Biotechnologies, Arcellx, Arch Oncology, Arcturus Therapeutics, Arcus Biosciences, Ardeagen, argenx, Ariceum Therapeutics, Arima Genomics, Arovella Therapeutics, ArriVent Biopharma, Arsenal Biosciences, ARTBIO, Artelo Biosciences, Arthrosi Therapeutics, Artios Pharma, Artiva Biotherapeutics, Artizan Biosciences, Arvinas, Asan Medical Center, Ascentage Pharma, Asher Bio, Asher Biotherapeutics, Asieris MediTech, Asieris Pharmaceuticals, AskGene Pharma, Astellas Pharma, Astellas Pharma US, Astex Pharmaceuticals, AstraZeneca, Asymchem Laboratories, Atara Biotherapeutics, Athebio, Athenex, Atlas Antibodies, AtomVie Global Radiopharma, Atossa Therapeutics, ATP, ATUM, AUM Biosciences, Aurigene Discovery Technologies, Australian and New Zealand Children’s Haematology / Oncology Group, Australian Nuclear Science and Technology Organisation, Autolomous, Autolus, Autonomous Therapeutics, Avacta, Avectas, Avenzo Therapeutics, AVEO Oncology, Avera Health, Aviceda Therapeutics, Avicenna Biosciences, Aviko Radiopharmaceuticals, AVM Biotechnology, Axcelead Drug Discovery Partners, Bach Biosciences, Baili Biopharmaceutical, BAKX Therapeutics, BAMF Health, Banner MD Anderson Cancer Center, Bayer, Baylor College of Medicine, Baylor Scott and White Research Institute, BC Cancer Agency, BCM Europe, Beactica, Beartooth Therapeutics, Be Biopharma, BeiGene, Beijing InnoCare Pharma, Belharra Therapeutics, Bellicum Pharmaceuticals, Bend Bioscience, BenevolentAI, Bennu Pharmaceuticals, BeOne Medicines, BerGenBio, Beroni Group, Be The Match BioTherapies, Beth Israel Deaconess Medical Center, Betta Pharmaceuticals, Beverly Hills Cancer Center, Beyond Cancer, Beyondspring Pharmaceuticals, BGN Technologies, Bicycle Therapeutics, BigHat Biosciences, Binghamton University, BinnoPharm, Bio-Manguinhos/Fiocruz, Bio-Rad Laboratories, Bio-Sourcing, Bio-Techne, Bio-Thera Solutions, Bioarchitech, biOasis Technologies, BioAtla, Biocare Medical, Biocept, BioCheetah, BioCina, BioCity Biopharma, Biocon, BioCopy, BiocurePharm, Biocytogen, Biodesix, Biodexa Pharmaceuticals, BioEclipse Therapeutics, BioElpida, Biofrontera Pharma, Biognosys, Biohaven Pharmaceuticals, BioInvent, BioKey, BiolineRX, Biological Dynamics, Biolojic Design, BioMark Diagnostics, Biomedical Advanced Research and Development Authority, Biomedical Catalyst Fund (UK), BioMed X Innovation Center, Biomica, Biomunex Pharmaceuticals, Bionaut Labs, Biond Biologics, BiOneCure Therapeutics, BioNex Solutions, BioNexus Gene Lab, BioNova Pharmaceuticals, BioNTech, BioNxt Solutions, Biortus Biosciences, BioSenic, Biosidus, Biosion, Biositu Pharmaceutical Technology, Biosplice, BioStrand, BioTheryX, Biotheus, BioTuring, BioVaxys, BioVectra, bitBiome, BJ Bioscience, Black Diamond Therapeutics, Blacksmith Medicines, Blackstone, Blau Pharma, Bliss Biopharmaceutical, Blood Centers of America, Bluebridge Technologies, Blue Note Therapeutics, Blueprint Medicines, BobcatBio, Boehringer Ingelheim, Bolt Biotherapeutics, Boostimmune, Boryung Pharmaceutical, BostonGene, Boston Immune Technologies and Therapeutics, Boston Pharmaceuticals, Boundless Bio, Bpifrance, BRAIN Biotech, BrainLAB, Brainomix, Brenus Pharma, BriaCell Therapeutics, BriaPro Therapeutics, BridgeBio Pharma, Bridge Biotherapeutics, Bridge Medicines, BridGene Biosciences, BrighGene Biomedical, BrightPath Biotherapeutics, Bright Peak Therapeutics, Brii Biosciences, Bristol-Myers Squibb, Broad Institute, Brooklyn ImmunoTherapeutics, Bugworks, Burning Rock, Busan Paik Hospital, BWXT Medical, BYOMass, Byondis, C2i Genomics, C4 Therapeutics, Calbiotech, Calian Group, Calico, Calidi Biotherapeutics, Califia Pharma, California Institute for Regenerative Medicine, Calithera Biosciences, Camargo Pharmaceutical Services, Cambridge Quantum Computing, Can-Fite BioPharma, CanariaBio, CancerCare, Cancer Focus Fund, Cancer Prevention and Research Institute of Texas, Cancer Research Horizons, Cancer Research Institute, Cancer Research UK, Cancer Science Institute of Singapore, CancerVax, Candel Therapeutics, Cannabics Pharmaceuticals, CanProbe, Cantex Pharmaceuticals, Caravan Biologix, Cardiff Oncology, Cardiff University, CARE, Care Access Research, Caribou Biosciences, Carina Biotech, Caring Cross, Caris Life Sciences, Carisma Therapeutics, Carrick Therapeutics, CARsgen, Cartexell, CARTI Cancer Center, Cartography Biosciences, Case Western Reserve University, CASI Pharmaceuticals, Castle Biosciences, Catalent, Catalyst Clinical Research, Catamaran Bio, Catholic University Leuven, Ceapro, Cedars-Sinai Medical Center, Cedilla Therapeutics, CeGaT, Celanese, Celcuity, Celest Therapeutics, Cell-Easy, Cellares, CellBion, Cellectis, Cellevolve Bio, Cellinfinity Bio, Cellipont Bioservices, Cellistic, Cellkey, CellMax Life, CellOrigin Biotech, Cell Point, Celltrion, CellType, Cellular Biomedicine, CellVax Therapeutics, Cellworks, Celularity, Cencora, Cend Therapeutics, Centre for Commercialization of Regenerative Medicine (CCRM), Centre for Probe Development and Commercialization, Centre Leon Berard, Century Therapeutics, Cerecor, Certara, Certis Oncology Solutions, Cevec Pharmaceuticals, CG Oncology, Champions Oncology, Chao Center, Charite Universitatsmedizin Berlin, Charles River Laboratories, Checkmate Pharmaceuticals, Checkpoint Therapeutics, Chemify, Chengdu Baiyu Pharmaceutical, Chime Biologics, Chimeric Therapeutics, China Grand Pharmaceutical, Chinese University of Hong Kong, Chinook Therapeutics, Chiome Bioscience, Chipscreen NewWay Biosciences, Chong Kun Dang, Chonnam National University, Chugai Pharmaceutical, CicloMed, Cidara Therapeutics, CiMaas, Cimeio Therapeutics, Circio, Circle Pharma, Cirna Diagnostics, Citius Oncology, Citius Pharmaceuticals, City of Hope, CK Life Sciences, Clarity Pharmaceuticals, Clarus Therapeutics, Clavius Pharmaceuticals, ClearNote Health, Cleave Therapeutics, Cleveland Clinic, Clinica Universidad Navarra, Clinigen, Clinscience, Clintrex Research, Clover Biopharmaceuticals, Clovis Oncology, CMG Pharmaceutical, CNAO Foundation, CNS Pharmaceuticals, Code Ocean, Coeptis Pharmaceuticals, Coeptis Therapeutics, Cofactor Genomics, Coherus Biosciences, CoImmune, Collaborations Pharmaceuticals, Colorado Melanoma Foundation, Columbia University, Columbia University Medical Center, CombiGene, Combotope Therapeutics, Compass Therapeutics, Complete Genomics, Complix, Compugen, ConcertAI, Concr, Congruence Therapeutics, Connect, Context Therapeutics, Convergent Bioscience, Convergent Therapeutics, Corbus Pharmaceuticals, Core Biotherapeutics, Cornell University, Cortice Biosciences, COTA, Covant Therapeutics, Creative Biolabs, Crescendo Biologics, Crescent Biopharma, Crinetics, CRISPR Therapeutics, Cromos Pharma, Crown Bioscience, CRT Pioneer Fund, CryoPort, CSPC Megalith Biopharmaceutical, CSPC Pharmaceutical Group, CStone Pharmaceuticals, CtM Biotech, CTMC, CTTQ-Akeso Biomed, Cue Biopharma, Cullgen, Cullinan Oncology, Culmination Bio, Cumberland Pharmaceuticals, Curadh MTR, Curasight, Curatis, Curebase, CureMatch, CURE Pharmaceutical, CureVac, Curiox Biosystems, Curis, Curium, Curtana Pharmaceuticals, Cybrexa Therapeutics, Cyclenium Pharma, Cyclica, Cytea Bio, Cytecare Cancer Hospitals, Cytocom, Cytodyn, CytoImmune Therapeutics, CytoLynx Therapeutics, CytoMed Therapeutics, CytomX Therapeutics, CytoReason, CytoSite Bio, Cytovance Biologics, Cytovation, CYTOVIA Therapeutics, DAAN Biotherapeutics, DAAN Bio Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Dalton Pharma Services, Dana-Farber Cancer Institute, Dana Farber Partners Cancer Care, Danaher, Danish Cancer Society Research Center, Danuo Science Group, Dartmouth College, DarwinHealth, Day One Biopharmaceuticals, DCx Biotherapeutics, Debiopharm, Dechra Pharmaceuticals, Deciphera Pharmaceuticals, Deepcell, Deep Lens, Deerfield Management, Defence Therapeutics, Deimos Biosciences, Densitas, Department of Defense, Derm-Biome Pharmaceuticals, DeuteRx, Deverra Therapeutics, Dewpoint Therapeutics, DiaCarta, Diaccurate, Diakonos Oncology, Dialectic Therapeutics, DIAN Diagnostics, Diaprost, Diatech Pharmacogenetics, DISCO Pharmaceuticals, Dispatch Bio, DisperSol Technologies, Diverse Biotech, Dizal Pharmaceutical, Dolbey, Dong-A Pharmaceutical, DotBio, DoveTree Medicines, Dr. Reddy's Laboratories, Dragonfly Therapeutics, Dragon Sail Pharmaceutical, Dren Bio, Drug Farm, DualityBio, Duke University, DxVx, Earendil Labs, Eckert & Ziegler, Eczacibasi Pharmaceuticals, Edison Oncology, Editas Medicine, eFFECTOR Therapeutics, Eikon Therapeutics, Eilean Therapeutics, EirGenix, Eisai, Elektrofi, Element Biosciences, Elevar Therapeutics, ElevateBio, Elevation Oncology, ELIAS Animal Health, Elicio Therapeutics, Eli Lilly, Elix, Ellipses Pharma, Elpis Biopharmaceuticals, Elpiscience, Elthera, EmendoBio, Emercell, Emergence Therapeutics, Emmaus Life Sciences, Emory University, Enara Bio, Endeavor BioMedicines, Endevica Bio, EnGeneIC, Enlivex, Enodia Therapeutics, Enosi Therapeutics, Ensem Therapeutics, Ensysce Biosciences, Enterprise Ireland, Enveric Biosciences, Envisagenics, Enzolytics, EOC Pharma, EpicentRx, Epic Sciences, EpimAb Biotherapeutics, Epiphany Dermatology, Epitopea, EpiVax Therapeutics, Epizyme, EQRx, Er-Kim, Erasca, Erasmus University Medical Center, ERS Genomics, ErVimmune, Escugen, Esperovax, ESSA Pharma, Essen University Hospital, Esteve, Etcembly, Eterna Therapeutics, eTheRNA immunotherapies, Eucure Biopharma, Euratom, Eureka Eurostars, Eureka Therapeutics, Eurobio Scientific, Eurofins Discovery, European Innovation Council, European Institute of Oncology (EIO), European Organization for Research and Treatment of Cancer, Eutilogics, Evariste, Evaxion Biotech, Evercyte, Everest Medicines, Evergreen Theragnostics, Eversana, EVerZom, Evinova, Evive Biotechnology, Evogene, EvolveImmune Therapeutics, Evonik Industries, Evopoint Biosciences, EVOQ Therapeutics, Evotec, EVQLV, Ewopharma, Exacis Biotherapeutics, Exact Sciences, Excellmab, Excellos, ExCellThera, Excelra, Exelixis, Exigent Research, ExonanoRNA, Exousia Pro, Experimental Drug Development Centre, Expert Systems Inc, Exscientia, Exuma Biotech, Eyam Vaccines and Immunotherapeutics, F-Star Therapeutics, Factor Bioscience, Factorial Biotechnologies, Fannin, Faraday Pharmaceuticals, FatiAbGen, Federation Bio, Fennec Pharmaceuticals, Ferring Pharmaceuticals, Ferronova, Fibrogen, Fidelion Diagnostics, Fight Colorectal Cancer, FineImmune Biotechnology, FivepHusion, Flagship Biosciences, Flagship Pioneering, Flame Biosciences, Flare Therapeutics, Flatiron Health, Florida Atlantic University Research, Foghorn Therapeutics, FogPharma, Food and Drug Administration (FDA), ForDoz Pharma, Foreseen Biotechnology, Foresee Pharmaceuticals, Foresight Diagnostics, Foresite Capital, FORMA Therapeutics, Formosa Pharmaceuticals, Formycon, Fortis Therapeutics, Fortrea, FORUS Therapeutics, Fosun Pharmaceutical, Foundation Medicine, Fox Chase Cancer Center, Francis Crick Institute, Fred Hutchinson Cancer Research Center, Freenome, Friends of Cancer Research, Fulgent Pharma, Full-Life Technologies, Fuse Oncology, Fusion Pharmaceuticals, Future Fields, FutureGen Biopharm, FyoniBio, G1 Therapeutics, G42 Healthcare, Gadeta, Gaeta Therapeutics, Gain Therapeutics, Galapagos, Galecto, Gamida Cell, Gastro-Intestinal Research Foundation, GATC Health, GC, GC Cell, GE Healthcare, GEICAM, Geisinger Health System, Gemelli Teaching Hospital, GEn1E Lifesciences, GeneCraft, GeneData, Genelux, Genentech, GeneQuantum Healthcare, General Inception, General Proximity, Generate Biomedicines, Geneseeq, Genesis Pharma, Genesis Therapeutics, Genetic Leap, Genevant Sciences, Genezen, GenFleet Therapeutics, Genhouse Bio, Genialis, Genmab, Genocea Biosciences, Genome and Company, Genome Diagnostics, Genome Insight, Genoscience, Genprex, GenScript Biotech, GenScript ProBio, Genuv, Georgetown University, George Washington University, Georgiamune, German Cancer Research Center, Gicell, GigaMune, GI Innovation, Gilead Sciences, Ginkgo BioWorks, Glenmark Pharmaceuticals, Glenmark Pharmaceuticals S.A., GlobalBio, Global Cancer Technology, Global Coalition for Adaptive Research, Gloria Biosciences, GlycoMantra, GlycoNex, Glycostem Therapeutics, Glycotope Biotechnology, Glykos, Glytherix, GNS Healthcare, GO2 Foundation for Lung Cancer, GOG Foundation, GO Therapeutics, Government of Ireland, GPCR Therapeutics, Gracell Biotechnologies, Grail, Granite Bio, Graviton Bioscience, Greenlight Biosciences, Greenwich LifeSciences, Grey Wolf Therapeutics, Grid Therapeutics, GRIT Biotechnology, Gritstone Bio, Groupe d'OncologieRadiothérapie Tête Et Cou, GSK, GT Apeiron Therapeutics, GT Biopharma, GT Medical Technologies, Guangzhou Fanen Biotechnology, Guangzhou Ruianbo Pharmaceutical Technology, Guangzhou Ruiao Biopharmaceutical Technology, Guardant Health, Guerbet, GV20 Therapeutics, H3 Biomedicine, Hadassah Medical Center, HaemaLogiX, Halozyme Therapeutics, Hamlet Pharma, HanAll Biopharma, HanAll Pharmaceuticals, HanchorBio, Handa Therapeutics, Hande Sciences, Handok Pharmaceuticals, Hangzhou CNK Therapeutics, Hangzhou Zhongmei Huadong Pharmaceutical, Hanmi Pharmaceutical, HanX Biopharmaceuticals, Harbinger Health, Harbour Biomed, Harpoon Therapeutics, Harvard Medical School, HavaH Therapeutics, HAYA Therapeutics, Haystack Oncology, HCW Biologics, HDT Bio, HebeCell, Hebrew University of Jerusalem, Heidelberg Pharma, Heligenics, Helio Genomics, Helmholtz Zentrum Munchen, Helsinn Healthcare, Helsinn Therapeutics, Hemispherian, Hemogenyx, Hengenix Biotech, Henlius Biotech, Hepion Pharmaceuticals, HiberCell, HIBio, HiFiBio, Hikma Pharmaceuticals, Hillstream BioPharma, HistoIndex, Hisun BioRay, HitGen, HK inno.N, Hoffmann La Roche, Hokkaido University, Holobeam Technologies, Honeycomb Biotechnologies, Hookipa Pharma, Horizon Europe, Hoth Therapeutics, HotSpot Therapeutics, Hox Therapeutics, Huadong Medicine, Huma, Humanitas University, Hummingbird Bioscience, Hutchmed, Huyabio International, Hyloris Pharmaceuticals, Hypospray Pharma, I-mab, Iambic Therapeutics, IASO Biotherapeutics, Iaso Pharmaceuticals, IBA, Ibex Medical Analytics, iBio, iCAD, Icahn School of Medicine at Mount Sinai, Ichnos Glenmark Innovation, Ichnos Sciences, Icon, IDEAYA Biosciences, Idorsia, IGM Biosciences, Ikena Oncology, Ikonopedia, Iksuda Therapeutics, Iktos, Ildong Pharmaceutical, Illumina, Imagene Labs, ImaginAb, IMBdx, Immagene, Immatics Biotechnologies, Immedica, Immix Biopharma, Immorna, Immune-Onc Therapeutics, Immuneel Therapeutics, Immuneering, ImmuneOncia Therapeutics, ImmuneOnco Biopharmaceuticals, Immune Therapeutics, Immunicom, ImmunityBio, ImmunoAdoptive Cell Therapy, Immunocore, ImmunoGen, ImmunoGenesis, Immunome, Immunomedics, Immunomic Therapeutics, ImmunoPrecise Antibodies, ImmunoScape, Immunovia, ImmuPharma, Immutep, ImmVira, IMPACT-AML, IMPACT Therapeutics, Imperial College London, Imugene, IMV, Imvaq Therapeutics, In4Derm, IN8bio, Inceptor Bio, Incyclix Bio, Incyte, Indapta Therapeutics, Indaptus Therapeutics, Indiana Biosciences Research Institute, Indivumed, InduPro Therapeutics, Infinimmune, Infinitusbio.AI, Inhibikase Therapeutics, Inhibitor Therapeutics, Inhibrx, Inivata, INmune Bio, InnDura Therapeutics, Innolake Biopharm, Innoplexus, Innosuisse, Innovate UK, Innovation Norway, Innovative Cellular Therapeutics, Innovative Medicines Initiative (IMI), Innovent Biologics, Inovio, Inserm, Insilico Medicine, InSitu Biologics, InSphero, Inspirna, Instil Bio, Institut Bergonie, Institut Curie, Institute for Follicular Lymphoma Innovation, Institute for Systems Biology, Institute of Cancer Research, Institut Gustave Roussy, Intas Pharmaceuticals, Integral Molecular, Integrated Biosciences, Integrated DNA Technologies, Integra Therapeutics, Intellia Therapeutics, Intelligent Scopes, Intensity Therapeutics, Intermountain Healthcare, Intima Bioscience, Invasight, Invenio Imaging, Invenra, Inventum Genetics, inviCRO, invIOs, InVirtuoLabs, Invitae, InVivoScribe, InxMed, IO Biotech, iOncologi, iOnctura, Ionetix, Ionis Pharmaceuticals, Ionova, Iovance Biotherapeutics, Ipsen, IQVIA, IRBM, Isofol Medical, Isologic Innovative Radiopharmaceuticals, Isotopia Molecular Imaging, Italian Association for the Study of Pancreas, iTeos Therapeutics, Iterion Therapeutics, ITM Isotopen Technologien, IUCT, Ix Therapeutics, Jackson Laboratory, Jacobio Pharma, Jacobio Pharmaceuticals, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janux Therapeutics, Jazz Pharmaceuticals, Jefferson Healthcare, JelloX Biotech, Jemincare, Jenga Biosciences, Jenthera Therapeutics, Jiangsu Aosaikang Pharmaceutical, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu Hengrui Pharmaceuticals, J Ints Bio, JMT-Bio, Jnana Therapeutics, Johannes Gutenberg University, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Josep Carreras Leukaemia Research Institute, Jounce Therapeutics, Joyo Pharmatech, JSR Life Sciences, Juniper Biologics, Junshi Biosciences, Jupiter Bioventures, Jura Bio, Juri Biosciences, JW Biotechnology, JW Therapeutics, K2bio, KAHR Medical, Kainos Medicines, Kalbe Genexine Biologics, KaliVir Immunotherapeutics, Kanvas Biosciences, Karkinos Healthcare, Karolinska Institute, Karolinska University Hospital, Kartos Therapeutics, Karyopharm Therapeutics, Kazia Therapeutics, Kelonia Therapeutics, Kelun-Biotech Biopharmaceutical, Keros Therapeutics, Keymed Biosciences, Kezar Life Sciences, Kincell Bio, Kineta, Kings College London, Kinnate Biopharma, Kiromic Biopharma, Kissei Pharmaceutical, Kite Pharma, Kiyatec, Knight Therapeutics, KOMO Biosciences, Korea Drug Development Fund, Korea Institute of Radiological and Medical Sciences, Kovina Therapeutics, Krankenhaus Nordwest, Kriya Therapeutics, Kronos Bio, KSQ Therapeutics, Kumquat Biosciences, Kura Oncology, Kuva Labs, Kymera Therapeutics, Kyowa Hakko Kirin, kyron.bio, LabConnect, LabGenius, Laboratory Corporation of America, Laekna, Laevoroc Oncology, La Jolla Institute for Allergy & Immunology, LaNova Medicines, Lantern Pharma, Lantheus Holding, Lassen Therapeutics, Latvian Institute of Organic Synthesis, LaunXP Biomedical, Lava Therapeutics, Leap Therapeutics, Lee Moffitt Cancer Center, Legend Biotech, LegoChem Biosciences, Lehigh Valley Health Network, Leica Biosystems, Leo Cancer Care, LEO Pharma, Lepu Biopharma, Les Laboratoires Servier, Leucid Bio, Leukemia & Lymphoma Society, LeukoCom, Leveragen, LG Chem, LianBio, Libera Bio, Life Magnetics, Life Raft Group, LifeStrands Genomics, LIfT BioSciences, LigaChem Biosciences, Ligand Pharmaceuticals, Light Horse Therapeutics, Lightpoint Medical, Lindis Biotech, Lineage Cell Therapeutics, Link Cell Therapies, LinKinVax, Lion TCR, Lipomedix Pharmaceuticals, Liquid Biosciences, Lisata Therapeutics, Little Warrior Foundation, Livzon Mabpharm, Lixte Biotechnology, Logomix, Longwood University, Lonza, LOTTE Biologics, Lotus Pharmaceuticals, Loxo Oncology, LTZ Therapeutics, Lubrizol, Lucence, Lukas Biomedical, Luminary Therapeutics, Lundquist Institute, Lung Cancer Foundation of America, Lung Cancer Initiative, Lung Cancer Research Foundation, LUNGevity Foundation, Lunit, Lupagen, Lyell Immunopharma, Lyvgen Biopharma, M2Gen, M42, MaaT Pharma, MabCare Therapeutics, Mablink Bioscience, Mabwell Bioscience, mAbXience, Macomics, Macrogenics, MagBio Genomics, Magic Leap, Magle Chemoswed, MagnaPharm Group, Magnet Biomedicine, MAIA Biotechnology, Maine Medical Center, Mainz Biomed, Manhattan BioSolutions, MapKure, Marengo Therapeutics, Maria Curie-Sklodowska University, Marker Therapeutics, Mark Foundation for Cancer Research, MASORI Therapeutic, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mass General Brigham, Massive Bio, Mawi DNA Technologies, Max-Delbruck Center for Molecular Medicine, Maxcyte, Mayo Clinic, McKesson, McMaster University, McQuade Center for Strategic Research and Development, MD Anderson Cancer Center, MDimune, Medac, Medexus Pharmaceuticals, Medial EarlySign, Medical College of Wisconsin, Medical Research Council, Medical University South Carolina, Medicenna Therapeutics, Medicines Discovery Catapult, Medicines Patent Pool Foundation, MEDiC Life Sciences, Medicovestor, Medidata Solutions, MediGene, MediLink Therapeutics, MediSix Therapeutics, Medison Pharma, Medivir, Medolife Rx, MedPacto, Medsenic, Medshine Discovery, Meharry Medical College, Meitheal Pharmaceuticals, Memorial Sloan Kettering Cancer Center, Memo Therapeutics, Menarini, Mendus, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Mersana Therapeutics, Merus, Mestag Therapeutics, Metagenomi, ME Therapeutics, Metis Therapeutics, MGFB, MGI Tech, Microba Life Sciences, Microbiotica, Micronoma, Microsoft, Microviable Therapeutics, Miltenyi Biotec, Mimetas, Minaris Regenerative Medicine, MindRank AI, Minghui Pharmaceutical, MiNK Therapeutics, Minotaur Therapeutics, Mirati Therapeutics, Mirror Biologics, MiRXES, Mission Bio, Mitsubishi Tanabe Pharma, Moderna, ModeX Therapeutics, Molcure, Molecular Partners, Molecular Targeting Technologies, Molecular Templates, Moleculin Biotech, Molecure, MOMA Therapeutics, Mongoose Bio, Monopar Therapeutics, Montai Therapeutics, Monte Rosa Therapeutics, Moonlight Bio, MorphoSys, Mor Research Applications, Mosaic ImmunoEngineering, Mosaic Therapeutics, Mount Sinai Health System, mProbe Laboratories, MSD, MS Pharma, MThera Pharma, Multidisciplinary Association for Psychedelics Studies, Multitude Therapeutics, Mundipharma, Mustang Bio, MyBiotics Pharma, Myeloid Therapeutics, Mymetics, myNEO, Myovant Sciences, Myriad Genetics, Myricx Bio, Mythic Therapeutics, Nagoya University Graduate School of Medicine, Nanjing KAEDI Biotech, Nanjing King-friend Biochemical Pharmaceutical, Nanjing Leads Biolabs, Nanobiotix, Nanocarry Therapeutics, Nanoform, NanoMab Technology, NanoSmart Pharmaceuticals, NanoString Technologies, NaNotics, NanoVation Therapeutics, NantOmics, Napo EU, Napo Pharmaceuticals, Nascent Biotech, Natera, National Cancer Center, National Cancer Center of Japan, National Cancer Centre Singapore, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Comprehensive Cancer Network (NCCN), National Health Service, National Institute for Bioprocessing Research and Training, National Institute of Neurological Disorders and Stroke, National Institutes of Health, National Research Council of Canada, National University Cancer Institute, National University of Ireland, Galway (NUI Galway), Nationwide Children’s Hospital, Nautilus Biotech, Naveris, Navidea Biopharmaceuticals, Navigo Proteins, Navrogen, NAYA Biosciences, nCage Therapeutics, NEC Bio Therapeutics, Nectin Therapeutics, NED Biosystems, Nektar Therapeutics, Nelum Pharma, NeoCura Bio-Medical Technology, Neogap Therapeutics, Neogene Therapeutics, Neogenomics, NeoImmuneTech, Neoleukin Therapeutics, Neomorph, NeoPharm, NeoPhore, Neoregen Biotech, NeoX Biotech, NeraCare, Nerviano Medical Sciences, Netherlands Cancer Institute, NETRIS Pharma, NeuCen BioMed, Neupharma, Neurix, Neurochase, Neurocrine Biosciences, Neutron Therapeutics, Neuvogen, New Day Diagnostics, Newsoara Biopharma, NewStem, New York Cancer & Blood Specialists, New York University Langone Health, Nexcella, Neximmune, NextCure, Next Generation Manufacturing Canada, NEXT Oncology, NextPoint Therapeutics, NextRNA Therapeutics, Nference, NGM Biopharmaceuticals, Nico, NiKang Therapeutics, Nilogen Oncosystems, Nimble Therapeutics, Niowave, Nippon Kayaku, Nippon Shinyaku, Nkarta Therapeutics, Nobelpharma, Noetik, Nona Biosciences, Nordic Nanovector, Nordic Society of Gynaecological Oncology, Norgine, Noria Therapeutics, Normunity, North Carolina State University, Northern RNA, NorthStar Medical Radioisotopes, Northwest Biotherapeutics, Northwestern University, NorthX Biologics, Norwegian Cancer Society, Notable Labs, Nouscom, NovAccess Global, NovaRock Biotherapeutics, Novartis, Novatim Immune Therapeutics, Novellus Biopharma, Novellus Therapeutics, Novelty Nobility, Novocure, Novogene, Novo Nordisk, NRG Oncology, nRichDX, Nuance Pharma, Nucleai, Nuclidium, NuclixBio, Numab, Nuntius Therapeutics, NuProbe, Nurix Therapeutics, Nuvation Bio, Nuvectis Pharma, Nvidia, NX Development, Nykode Therapeutics, NYU Grossman School of Medicine for Preclinical and Clinical Research, NYU Langone Medical Center, O2nix Bio, Oasmia Pharmaceutical, OBI Pharma, Ocean Biomedical, Odeon Therapeutics, Odimma Therapeutics, Ohio State University, Olatec Therapeutics, Olema Oncology, Olimmune, Olink Proteomics, Olivia Newton-John Cancer Research Institute, Omega Therapeutics, Omico, OmniAb, OmniaBio, OmniSpirant, Ona Therapeutics, Oncidium Foundation, Onco-Innovations, OncoBay Clinical, OncoC4, Oncode Institute, Oncodesign, OncoDNA, Oncoheroes Biosciences, OncoHost, Oncology Pharma, OncoMyx Therapeutics, OncoNano Medicine, Onconova Therapeutics, Oncopeptides, OncoResponse, Oncorus, OncoSec Medical, Oncoshot, Oncosyne, OncoVerity, Oncovir, Oncovita, OncoX BioPharma, OncoZenge, Oncternal Therapeutics, OnCusp Therapeutics, OncXerna Therapeutics, OneThree Biotech, ONK Therapeutics, Ono Pharmaceutical, Ontada, Onward Therapeutics, OpenBench, Optellum, Optieum Biotechnologies, Optimeos Life Sciences, Orange Grove Bio, Orano Med, OrbiMed Asia Partners, Orbit Discovery, Ordaos Bio, Oregon Health Sciences University, Oregon Therapeutics, Organon, Ori Biotech, ORIC Pharmaceuticals, OrigiMed, Orion, Orionis Biosciences, Orna Therapeutics, Oscotec, OSE Immunotherapeutics, Osel, OSR Holdings, Ossium Health, Ostentus Therapeutics, Otsuka, Ottawa Health Research Institute, Ottawa Hospital Research Institute, Ottimo Pharma, Outpace Bio, Owkin, Owlstone Medical, Oxford Biomedica Solutions, Oxford BioTherapeutics, Oxford Drug Design, Oxford Vacmedix, Oxyrane UK, Ozette Technologies, Pacific Biosciences, PACT Pharma, Pacylex, Paige, Palleon Pharmaceuticals, Panbela Therapeutics, Pangea Biomed, Panolos Bioscience, Papyrus Therapeutics, Paradigm, Paragon Therapeutics, Parexel, Parthenon Therapeutics, Partnership for Accelerating Cancer Therapies, Partner Therapeutics, PathAI, PathomIQ, Pathos AI, PCI Biotech, PDS Biotechnology, Pearl Bio, Pelthos Therapeutics, Pepscan, PeptiDream, Peptron, Percheron Therapeutics, Persephone Biosciences, Personal Genome Diagnostics, Personalis, PersonGen BioTherapeutics, Perspective Therapeutics, Peter MacCallum Cancer Institute, Pfizer, Pfizer Canada, Phanes Therapeutics, PharmAbcine, PharmaEssentia, PharmaJet, PharmaLogic, PharmaMar, Pharmanovia, Pharmapark, Phase Genomics, Phebra, Phenomic AI, PhenoVista Biosciences, Pheon Therapeutics, Philochem, Philogen, Phio Pharmaceuticals, PhoreMost, Phost’in Therapeutics, Photocure ASA, PhotonPharma, Phrontline Biopharma, PierianDx, Pieris Pharmaceuticals, Pierre Fabre, Pillar Biosciences, PineTree Therapeutics, Pint Pharma, Pionyr Immunotherapeutics, Piramal, Plan France Relance, PlantForm, PlantPraxis Biotecnologia, Pleco Therapeutics, Pluristyx, Plus Therapeutics, PlusVitech, PMV Pharma, POINT Biopharma, Polaris Group, PolarisQB, Polifarma, PolyPid, Pompeu Fabra University, Portage Biotech, Porton Biologics, Porton Pharma Solutions, Poseida Therapeutics, Precirix, Precision BioSciences, Precision for Medicine, Precision Molecular, Precision NanoSystems, Precision NeuroMed, Predicine, Predictive Oncology, Pregene Biopharma, Prelude Therapeutics, Presage Biosciences, Prestige BioPharma, Prime Medicine, Prisma Health, PRISM BioLab, Privo Technologies, ProBioGen, Procare Health, ProEn Therapeutics, Profluent Bio, ProfoundBio, Profound Medical, Progenetics, Prokarium, Prolium Bioscience, Promega, Propanc Biopharma, Propella Therapeutics, Prophase Labs, Prosoma Digital Therapeutics, Prostate Cancer Clinical Trials Consortium, ProteinTech, ProteoMediX, Proteros biostructures, Providence Cancer Institute, Providence Therapeutics, PSI CRO, PsiVac, PT Elion Medika, PT Etana Biotechnologies, Puma Biotechnology, Purdue Research Foundation, Purdue University, Pure Biologics, PureForm Global, Pure MHC, PureTech Health, Purisys, Purple Biotech, Pyramid Biosciences, Pyxis Oncology, Q-Gen Cell Therapeutics, Q BioMed, QDX, QED Therapeutics, QIAGEN, Qilu Pharmaceutical, Quadira Biosciences, Quadri Pharmaceuticals, Qualigen, Quantgene, Quantum Leap Health Care Collaborative, Qubit Pharmaceuticals, Quebec Consortium for Drug Discovery, Quebec Heart and Lung Institute, Queen Mary University of London, Queensland Institute of Medical Research (QIMR), Queensland University of Technology, Queens University Belfast, Quercis Pharma, Quest Diagnostics, Qurient, R-Pharm, Race Oncology, Radboud University Nijmegen, Radiance Biopharma, Radiomedix, Radionetics Oncology, Radiopharm Theranostics, Rain Oncology, Rakovina Therapeutics, Rakuten Medical, Rambam Medical Center, Ranok Therapeutics, Rappta Therapeutics, Ratio Therapeutics, RayzeBio, Realm IDx, Receptor.AI, Recro Pharma, Recurrent Respiratory Papillomatosis Foundation, Recursion, RedHill Biopharma, Redwood Bioscience, Redx Pharma, RefleXion Medical, Refuge Biotechnologies, Regen BioPharma, Regeneron Pharmaceuticals, Regional Cancer Institute of Montpellier, Regnum, Regor Therapeutics, Relation Therapeutics, Relay Therapeutics, RemeGen, Remix Therapeutics, Renovaro BioSciences, RenovoRx, Renown Institute for Health Innovation, Repare Therapeutics, Repertoire Immune Medicines, Replay, Replimune, ReproCell, Reset Pharmaceuticals, Res Nova Bio, Reveal Genomics, ReviR Therapeutics, Revitope Oncology, Revolution Medicines, Rgene, Rgenta Therapeutics, Ribon Therapeutics, Richard Wolf Medical Instruments, Rigel Pharmaceuticals, Rivaara Immune, RK Pharma, Roche, Roche Molecular Systems, Rocket VR Health, Roivant Sciences, Rondo Therapeutics, Roswell Park Cancer Institute, Royal Marsden Hospital, RubrYc Therapeutics, Rutgers University, Rxilient Biotech, Ryvu Therapeutics, Rznomics, SAGA Diagnostics, Sairopa, Salarius Pharmaceuticals, Salk Institute, Samsung Bioepis, Samsung Biologics, Samyang Biopharmaceuticals, Sana Biotechnology, SandboxAQ, Sandoz, Sanford Burnham Institute, Sanofi, San Raffaele Hospital, SanReno Therapeutics, Sant Joan de Déu-Barcelona Children’s Hospital, Sanwa Kagaku Kenkyusho, Sanyou Biopharmaceuticals, Sapien Biosciences, Sapience Therapeutics, Sapu Bioscience, Sarah Cannon Research Institute, Sarcoma Oncology Center, Sartorius Stedim Biotech, SATT Nord, Scailyte, Scancell, Scenic Biotech, Schrodinger, SciClone Pharmaceuticals, Science 37, Scorpion Therapeutics, Scribe Therapeutics, Scripps Research Institute, Seagen, Seattle Children's Therapeutics, Seattle Genetics, Sebela Pharmaceuticals, Secarna Pharmaceuticals, Seed Therapeutics, Seibersdorf Laboratories, Selexis, SELLAS Life Sciences Group, Selvita, Sema4, SEngine Precision Medicine, Senhwa Biosciences, Sensei Biotherapeutics, Senti Biosciences, Sentinel Diagnostics, Seoul National University, SequMed, SeraNovo, Sermonix Pharmaceutical, Serotiny, Sesen Bio, Seven and Eight Biopharmaceuticals, SevenScore Pharmaceuticals, SFJ Pharmaceuticals, Shanghai Affinity Biopharmaceutical, Shanghai Lishan Biopharmaceuticals, Shanghai Pharmaceutical, Sharp HealthCare, Shasqi, Shenzhen Chipscreen Biosciences, Shepherd Therapeutics, Shimadzu, SHINE Technologies, Shoreline Biosciences, Shorla Oncology, Shorla Pharma, Shuttle Pharmaceuticals, Sibylla Biotech, Sidewinder Therapeutics, Sidney Kimmel Cancer Center, Sierra Oncology, SIGA Technologies, Silexion Therapeutics, SillaJen, SimBioSys, Simcere Pharmaceuticals, Simcere Zaiming, Simcha Therapeutics, Similis Bio, Simnova, Simsen Diagnostics, Singapore General Hospital, Singlera Genomics, Singleron Biotechnologies, Singular Genomics Systems, Sino Biopharm, Sinorda Biomedicine, Siren Biotechnology, Sirtex Medical, SiSaf, SK Biopharmaceuticals, SkyePharma, Skyhawk Therapeutics, Smart Immune, SN BioScience, Societal CDMO, Soligenix, Solstice Oncology, Solve Therapeutics, Sona Nanotech, Sonnet BioTherapeutics, Sony, Sookmyung Women's University, SOPHiA Genetics, Sorrento Therapeutics, Sosei Heptares, SOTERIA Precision Medicine Foundation, SOTIO, Spanios, Spanish Lung Cancer Group, Spanish National Cancer Research Centre, Spanish National Research Council, Spanish State Research Agency, SparX Biopharmaceutical, Specialised Therapeutics, SpectronRx, Spectrum Pharmaceuticals, SpringWorks Therapeutics, Sprint Biosciences, St. Baldrick's Foundation, Stablepharma, STADA Arzneimittel, Stand Up To Cancer, Stanford University, Stanford University School of Medicine, StarkAge Therapeutics, Starpharma, Starton Therapeutics, Statera Biopharma, Stella Diagnostics, Stemline Therapeutics, Step Pharma, SteroTherapeutics, Stimunity, Storm Therapeutics, Strand Therapeutics, Strata Oncology, SUDA Pharmaceuticals, Sumitomo Dainippon Pharma, Summit Therapeutics, Sun Pharma Advanced Research Company, Sun Pharmaceutical, SunRock Biopharma, Sunshine Biopharma, Sunstone Therapies, Surface Oncology, Susan G. Komen for the Cure, Sutro Biopharma, Suzhou Porton Advanced Solutions, Suzhou Puhe BioPharma, Suzhou Runxin Biotechnology, Swedish Orphan Biovitrum, Swiss Institute of Bioinformatics (SIB), Swiss Pharmaceutical, Swiss Rockets, Syapse, Syena, Symbasis, Synaffix, Syncromune, Syndax Pharmaceuticals, SynDevRx, Syndivia, Syneos Health, Synfini, Syngene, Synimmune, Synnovation Therapeutics, Synthekine, Syros Pharmaceuticals, Systimmune, T-Cure Bioscience, Tachyon Therapeutics, TAE Life Sciences, Tahoe Therapeutics, Taiho, Takeda Oncology, Takeda Pharmaceutical, Talem Therapeutics, Tallac Therapeutics, Talus Bioscience, Tampa General Hospital Cancer Institute, Targovax, Tasly Pharmaceuticals, Tavotek Biotherapeutics, Tavros Therapeutics, TC BioPharm, TCG Labs Soleil, TCR2 Therapeutics, Tegmine Therapeutics, Telix Pharmaceuticals, Tella, Tempest Therapeutics, Tempus, Tentarix Biotherapeutics, Teon Therapeutics, Terray Therapeutics, TerThera, Terumo Blood and Cell Technologies, Tesaro, Tesis Biosciences, Tessa Therapeutics, Tessellate Bio, Teva Pharmaceutical Industries, Texcell, TFC Therapeutics, Tharimmune, The Jackson Laboratory, The Parker Institute For Cancer Immunotherapy, Therabest, Theragen, Theragent, Theragnostics, Theralase, Therapeutic Solutions International, Theratechnologies, Theriva Biologics, Thermo Fisher Scientific, Theseus Pharmaceuticals, ThinkingNodeLife, Third Arc Bio, Thomas Jefferson University, TILT Biotherapeutics, Tiziana Life Sciences, Totus Medicines, Touchlight, Tracer Biotechnologies, TRACON Pharmaceuticals, Transcenta, TransCode Therapeutics, Transgene, Translational Genomics Research Institute, TransThera, TransThera Sciences, Traverse Biosciences, Treadwell Therapeutics, TreeFrog Therapeutics, Treehill Partners, Treventis, TRIANA Biomedicines, Trigone Pharma, TRIGR Therapeutics, Trinity College Dublin, TriSalus Life Sciences, Triumvira Immunologics, TScan Therapeutics, TTC, Tubulis, TuHURA Biopharma, TuHURA Biosciences, TumorGen, Turbine, Turn Biotechnologies, Turning Point Therapeutics, Turnstone Biologics, TwinStrand Biosciences, Twinstrand Therapeutics, Twist Bioscience, TYG Oncology, Ubiquigent, Ubix Therapeutics, uBriGene Biosciences, UCB, Ultima Genomics, Umoja Biopharma, Undisclosed Company, United Immunity, Univeristy of Durham, Universal Cells, University College London, University Health Network, University Hospitals Case Medical Center, University Medical Center Utrecht, University of Alabama at Birmingham, University of Amsterdam, University of Antwerp, University of Bern, University of Bordeaux I, University of British Columbia, University of Calgary, University of California, Davis, University of California, San Diego, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of California Santa Barbara, University of Central Florida Research Foundation, University of Chicago, University of Colorado, University of Dundee, University of Edinburgh, University of Florida, University of Granada, University of Heidelberg, University of Iowa, University of Jaen, University of Kansas, University of Lausanne, University of Leipzig, University of Louisville, University of Manchester, University of Marburg, University of Maryland, University of Maryland Baltimore, University of Massachusetts, University of Miami, University of Michigan, University of Minnesota, University of Missouri, University of Montreal, University of Newcastle, University of New Mexico, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Quebec, University of Queensland, University of Rochester, University of Rochester Medical Center, University of Sheffield, University of Southampton, University of South Australia, University of Sydney, University of Texas Health SCience Center at San Antonio, University of Texas Southwestern Medical Center, University of Utah, University of Virginia, University of Washington, University of Wisconsin, University of Wisconsin Carbone Cancer Center (UWCCC), University of Wollongong, Unleash Immuno Oncolytics, Unnatural Products, Unravel Biosciences, UroGen Pharma, UroGPO, UroViu, US Government, US Oncology Research, US WorldMeds, Valence Discovery, Vall d’Hebron Research Institute, Valo Therapeutics, Varian Medical Systems, Variational AI, Vaxalto Biotherapeutics, Vaximm, VBI Vaccines, Vector Pharma FZCO, VelaVigo, Veracyte, Verastem, Veraxa Biotech, Verily, VerImmune, Verismo Therapeutics, Vernalis, Vertex Pharmaceuticals, Veru, VIB, Vibliome Therapeutics, Viewpoint Molecular Targeting, Vignette Bio, Vinnova, Viome, Vipergen, Vir Biotechnology, ViroCell Biologics, Virogen, Vittoria Biotherapeutics, ViVerita Therapeutics, Vividion Therapeutics, Volastra Therapeutics, VolitionRX, Voltron Therapeutics, Vor Biopharma, Voronoi, Vuja De Sciences, Vyant Bio, VyGen-Bio, VYNE Therapeutics, Vyriad, Vysioneer, Wake Forest University, Wanchunbulin, Warpnine, Waseda University, Washington University in St Louis, Watchmaker Genomics, Weizmann Institute, Wellmarker Bio, Welton Pharma, Werewolf Therapeutics, Whitehawk Therapeutics, White Lion Capital, Wilson Wolf, Wisconsin Alumni Research Foundation, Wonkwang University, Worldwide Clinical Trials, WUGEN, Wuxi Apptec Laboratory Services, WuXi Biologics, Wuxi STA, WuXi XDC, WY Biotech, XBiotech, xCures, Xencor, Xenetic Biosciences, Xiamen Amoytop Biotech, Xiamen Biotime Biotechnology, Xilio Therapeutics, Xilis, XNK Therapeutics, Xspray Pharma, XtalPi, Xuanzhu Biopharma, Xyphos Biosciences, Y-Biologics, Y-mAbs Therapeutics, Yale Cancer Center, Yale School of Medicine, Yale University, Yantai Lannacheng Biotechnology, Yatiri Bio, Yeda Research and Development Company, Yemaachi Biotech, Yingli Pharma, Yissum Research Development, Ymmunobio, Yuhan Corporation, YUMAB, Zai Lab, ZAI Laboratory, Zelgen, Zelluna Immunotherapy, Zenith Epigenetics, Zentalis Pharmaceuticals, Zephyr AI, Zerion Pharma, Zetagen Therapeutics, Zhejiang Doer Biotechnology, Zion Pharmaceuticals, Zonsen PepLib Biotech, Zydus Cadila, Zydus Lifesciences, Zymeworks, ZYUS Life Sciences

Methodology

About Current Partnering

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.

Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.

Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

Company press releases and announcements
SEC filings and equivalent regulatory disclosures
Company and investor presentations
Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.

Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

Licensing and co-development
Research and collaborative R&D
Manufacturing, supply, and distribution
Commercialisation and co-promotion
Equity investments, joint ventures, and asset transactions
Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.

Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

Financial terms — including upfront payments, milestones, and royalties
Rights allocation — development, manufacturing, and commercialization responsibilities
Deal structure — exclusivity, territorial scope, and agreement type
Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

Therapy area and technology type
Stage of development
Asset type and deal components
Geographic scope and exclusivity
Source documentation, including press releases and SEC filings

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.

Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

How financial mechanisms are defined and triggered
How responsibilities are operationalised between parties
How flexibility, risk, and control are allocated within agreements

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:

Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight

Common use cases include:

Benchmarking comparable transactions
Supporting valuation and deal structuring
Preparing for negotiations
Evaluating potential partners
Informing internal strategy with real-world evidence

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.